Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Development of Small Molecule Inhibitors for Metastatic Cancer
share announcement

Development of Small Molecule Inhibitors for Metastatic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5356

Special Issue Editor

Prof. Dr. Deborah Lannigan

E-Mail Website
Guest Editor
1. Departments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
2. Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
3. Department of Biomedical Engineering, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Interests: small molecule inhibitors; drug development; cancer

Special Issue Information

Dear Colleagues,

Identification of effective therapies for the treatment of metastasis for any cancer remains an elusive goal, and meeting this goal is essential for achieving substantial improvement in cancer patient outcomes. Extensive efforts are currently underway to develop small molecule inhibitors for the numerous protein targets that appear to be important in regulating metastatic processes.  However, as of yet, a small molecule inhibitor has not achieved FDA approval for any cancer type. The objective of this issue is to highlight drug development efforts in the area of small molecule inhibitors that are focused on metastatic cancers.

In this Special Issue, original research articles and reviews are welcome.

I look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Prof. Dr. Deborah Lannigan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metastasis
  • chemical biology
  • drug development
  • small molecule inhibitor
  • metastatic process

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1187 KiB  
Review
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams
by Massimo Serra, Davide Rubes, Sergio Schinelli and Mayra Paolillo
Cancers 2023, 15(16), 4173; https://doi.org/10.3390/cancers15164173 - 18 Aug 2023
Cited by 2 | Viewed by 1101
Abstract
Metastasis is the main cause of anti-cancer therapy failure, leading to unfavorable prognosis for patients. The true challenge to increase cancer patient life expectancy by making cancer a chronic disease with periodic but manageable relapses relies on the development of efficient therapeutic strategies [...] Read more.
Metastasis is the main cause of anti-cancer therapy failure, leading to unfavorable prognosis for patients. The true challenge to increase cancer patient life expectancy by making cancer a chronic disease with periodic but manageable relapses relies on the development of efficient therapeutic strategies specifically directed against key targets in the metastatic process. Traditional chemotherapy with classical alkylating agents, microtubule inhibitors, and antimetabolites has demonstrated its limited efficacy against metastatic cells due to their capacity to select chemo-resistant cell populations that undergo epithelial-to-mesenchymal transition (EMT), thus promoting the colonization of distant sites that, in turn, sustain the initial metastatic process. This scenario has prompted efforts aimed at discovering a wide variety of small molecules and biologics as potential anti-metastatic drugs directed against more specific targets known to be involved in the various stages of metastasis. In this short review, we give an overview of the most recent advances related to important families of antimetastatic small molecules: intracellular tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, KRAS inhibitors, and integrin antagonists. Although the majority of these small molecules are not yet approved and not available in the drug market, any information related to their stage of development could represent a precious and valuable tool to identify new targets in the endless fight against metastasis. Full article
(This article belongs to the Special Issue Development of Small Molecule Inhibitors for Metastatic Cancer)
►▼ Show Figures

Graphical abstract

34 pages, 1093 KiB  
Review
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
by Mauro Viganò, Marta La Milia, Maria Vittoria Grassini, Nicola Pugliese, Massimo De Giorgio and Stefano Fagiuoli
Cancers 2023, 15(6), 1766; https://doi.org/10.3390/cancers15061766 - 14 Mar 2023
Cited by 7 | Viewed by 3821
Abstract
Small molecule protein kinase inhibitors (PKIs) have become an effective strategy for cancer patients. However, hepatotoxicity is a major safety concern of these drugs, since the majority are reported to increase transaminases, and few of them (Idelalisib, Lapatinib, Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Sunitinib) [...] Read more.
Small molecule protein kinase inhibitors (PKIs) have become an effective strategy for cancer patients. However, hepatotoxicity is a major safety concern of these drugs, since the majority are reported to increase transaminases, and few of them (Idelalisib, Lapatinib, Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Sunitinib) have a boxed label warning. The exact rate of PKI-induced hepatoxicity is not well defined due to the fact that the majority of data arise from pre-registration or registration trials on fairly selected patients, and the post-marketing data are often based only on the most severe described cases, whereas most real practice studies do not include drug-related hepatotoxicity as an end point. Although these side effects are usually reversible by dose adjustment or therapy suspension, or by switching to an alternative PKI, and fatality is uncommon, all patients undergoing PKIs should be carefully pre-evaluated and monitored. The management of this complication requires an individually tailored reappraisal of the risk/benefit ratio, especially in patients who are responding to therapy. This review reports the currently available data on the risk and management of hepatotoxicity of all the approved PKIs. Full article
(This article belongs to the Special Issue Development of Small Molecule Inhibitors for Metastatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop